Mainstream Capital Management LLC Increases Holdings in Eli Lilly and Company $LLY

Key Points

• Mainstream Capital Management LLC increased its holdings in Eli Lilly and Company by 41.0% during the second quarter, now owning 2,298 shares valued at approximately $1,791,000.
• Despite a strong quarterly earnings report exceeding analysts' expectations, several research firms have adjusted their ratings on Eli Lilly, with Erste Group Bank downgrading it from "buy" to "hold".
• Eli Lilly's stock is currently trading at $747.29, with a fifty-two week range between $623.78 and $939.30, and it holds a market capitalization of $707.27 billion.

Mainstream Capital Management LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 41.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,298 shares of the company's stock after purchasing an additional 668 shares during the quarter. Eli Lilly and Company makes up 1.3% of Mainstream Capital Management LLC's portfolio, making the stock its 20th biggest holding. Mainstream Capital Management LLC's holdings in Eli Lilly and Company were worth $1,791,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. WestEnd Advisors LLC raised its position in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after buying an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company during the first quarter valued at $27,000. Citizens National Bank Trust Department increased its holdings in Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in Eli Lilly and Company in the 1st quarter worth $40,000. Finally, Mascagni Wealth Management Inc. bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $43,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $747.29 on Wednesday. The stock's fifty day moving average is $736.98 and its 200 day moving average is $768.86. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $939.30. The firm has a market capitalization of $707.27 billion, a PE ratio of 48.84, a PEG ratio of 1.05 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Analyst Ratings Changes

LLY has been the topic of several research reports. Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. DZ Bank raised Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Hsbc Global Res upgraded Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. HSBC raised shares of Eli Lilly and Company from a "reduce" rating to a "hold" rating and raised their target price for the company from $675.00 to $700.00 in a report on Wednesday, August 27th. Finally, Berenberg Bank reaffirmed a "hold" rating and set a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $939.61.

Insiders Place Their Bets

In other Eli Lilly and Company news, Director Jamere Jackson bought 200 shares of the company's stock in a transaction on Friday, August 8th. The stock was acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gabrielle Sulzberger purchased 117 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the acquisition, the director owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock valued at $2,894,841 over the last quarter. Corporate insiders own 0.14% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.